These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study. Ward C J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822 [TBL] [Abstract][Full Text] [Related]
8. Neuroleptic malignant syndrome without neuroleptics. Ong KC; Chew EL; Ong YY Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199 [TBL] [Abstract][Full Text] [Related]
9. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079 [TBL] [Abstract][Full Text] [Related]
10. Management for motor and non-motor complications in late Parkinson's disease. Chan DK; Cordato DJ; O'Rourke F Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408 [TBL] [Abstract][Full Text] [Related]
11. Hallucinations and psychosis in Parkinson's disease. Rabey JM Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547 [TBL] [Abstract][Full Text] [Related]
12. [Prevention and treatment of malignant syndrome in patients with Parkinson's disease]. Kuno S Nihon Rinsho; 2004 Sep; 62(9):1721-4. PubMed ID: 15462391 [TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Encarnacion EV; Hauser RA Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609 [TBL] [Abstract][Full Text] [Related]
14. Emergency presentations of Parkinson's disease: early recognition and treatment are crucial for optimum outcome. Ghosh R; Liddle BJ Postgrad Med J; 2011 Feb; 87(1024):125-31. PubMed ID: 21106801 [TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035 [TBL] [Abstract][Full Text] [Related]
16. Treatment of motor dysfunction in Parkinson's disease: an overview. Thobois S; Delamarre-Damier F; Derkinderen P Clin Neurol Neurosurg; 2005 Jun; 107(4):269-81. PubMed ID: 15885384 [TBL] [Abstract][Full Text] [Related]
17. Current strategies in the treatment of Parkinson's disease and a personalized approach to management. Diaz NL; Waters CH Expert Rev Neurother; 2009 Dec; 9(12):1781-9. PubMed ID: 19951137 [TBL] [Abstract][Full Text] [Related]
18. A case of malignant syndrome associated with a parkinsonism patient. Sanga M; Nomura S Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Apr; 23(2):91-5. PubMed ID: 12762221 [TBL] [Abstract][Full Text] [Related]
19. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward. Evans AH; Lawrence AD; Cresswell SA; Katzenschlager R; Lees AJ Mov Disord; 2010 May; 25(7):867-76. PubMed ID: 20461804 [TBL] [Abstract][Full Text] [Related]
20. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]